RNA interference in the brain inhibits neurodegeneration in a polyglutamine disease, SCA1. Is this now the way forward for the clinical treatment of certain genetic disorders (pages 816–820)?
This is a preview of subscription content, log in via an institution to check access.
Renee Lucas
References
Elbashir, S.M. et al. Nature 411, 494–498 (2001).
Caplen, N.J., Parrish, S., Imani, F., Fire, A. & Morgan, R.A. Proc. Natl. Acad. Sci. USA 98, 9742–9747 (2001).
Xia, H. et al. Nat. Med. 8, 816–820 (2004).
Schols, L., Bauer, P., Schmidt, T., Schulte, T. & Riess, O. Lancet Neurol 3, 291–304 (2004).
Taylor, J.P., Hardy, J. & Fischbeck, K.H. Science 296, 1991–1995 (2002).
Paulson, H. Nat. Med. 9, 825–826 (2003).
Caplen, N.J. Gene Ther. 11, in the press (2004).
Dykxhoorn, D.M., Novina, C.D. & Sharp, P.A. Nat. Rev. Mol. Cell. Biol. 4, 457–467 (2003).
Flotte, T. Gene Ther. 11, 805–810 (2004).
Howard, K. Nat. Biotechnol. 21, 1117–1118 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Caplen, N. RNAi quashes polyQ. Nat Med 10, 775–776 (2004). https://doi.org/10.1038/nm0804-775
Issue Date:
DOI: https://doi.org/10.1038/nm0804-775
- Springer Nature America, Inc.